BACKGROUND: Recent evidence has shown that community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is less virulent than traditional hospital-associated MRSA. We explored whether the antimicrobial susceptibilities of the different strains account for their disparity in clinical virulence. METHODS: This 10-year retrospective cohort study enrolled 291 patients with community-onset, healthcare-associated MRSA bacteremia. The vancomycin minimum inhibitory concentration (MIC) and staphylococcal cassette chromosome mec (SCCmec) type were determined for all isolates. CA-MRSA was defined as an isolate possessing the SCCmec type IV or V genes, and hospital-associated MRSA (HA-MRSA) was defined as an isolate possessing SCCmec type I, II, or III genes. Low and high vancomycin MICs were defined as MICs of ≤1 and ≥2 μg/mL, respectively. Patients with bacteremia due to CA-MRSA with a low vancomycin MIC (n = 111), due to HA-MRSA with a low vancomycin MIC (n = 127), or due to HA-MRSA with a high vancomycin MIC (n = 47) entered the outcome analysis. The outcomes of the 2 HA-MRSA bacteremia groups were compared to those of the CA-MRSA bacteremia group. RESULTS: Treatment failure was observed in 35 (31.5%), 59 (46.5%), and 27 (57.4%) of patients with low-vancomycin-MIC CA-MRSA, low-vancomycin-MIC HA-MRSA, and high-vancomycin-MIC HA-MRSA bacteremia, respectively. After adjustment for potential confounding factors, the risk of treatment failure was significantly higher among patients with low-vancomycin-MIC HA-MRSA (adjusted odds ratio [aOR], 1.853; 95% confidence interval [CI], 1.006-3.413) and high-vancomycin-MIC HA-MRSA (aOR, 2.393; 95% CI, 1.079-5.309), compared with patients with low-vancomycin-MIC CA-MRSA. CONCLUSIONS: The higher risk for treatment failure among patients with traditional hospital-associated MRSA infections, compared with patients with CA-MRSA infections, is independent of the vancomycin MIC, suggesting a potential intrinsic strain-specific virulence effect.
BACKGROUND: Recent evidence has shown that community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is less virulent than traditional hospital-associated MRSA. We explored whether the antimicrobial susceptibilities of the different strains account for their disparity in clinical virulence. METHODS: This 10-year retrospective cohort study enrolled 291 patients with community-onset, healthcare-associated MRSA bacteremia. The vancomycin minimum inhibitory concentration (MIC) and staphylococcal cassette chromosome mec (SCCmec) type were determined for all isolates. CA-MRSA was defined as an isolate possessing the SCCmec type IV or V genes, and hospital-associated MRSA (HA-MRSA) was defined as an isolate possessing SCCmec type I, II, or III genes. Low and high vancomycin MICs were defined as MICs of ≤1 and ≥2 μg/mL, respectively. Patients with bacteremia due to CA-MRSA with a low vancomycin MIC (n = 111), due to HA-MRSA with a low vancomycin MIC (n = 127), or due to HA-MRSA with a high vancomycin MIC (n = 47) entered the outcome analysis. The outcomes of the 2 HA-MRSA bacteremia groups were compared to those of the CA-MRSA bacteremia group. RESULTS:Treatment failure was observed in 35 (31.5%), 59 (46.5%), and 27 (57.4%) of patients with low-vancomycin-MIC CA-MRSA, low-vancomycin-MIC HA-MRSA, and high-vancomycin-MIC HA-MRSA bacteremia, respectively. After adjustment for potential confounding factors, the risk of treatment failure was significantly higher among patients with low-vancomycin-MIC HA-MRSA (adjusted odds ratio [aOR], 1.853; 95% confidence interval [CI], 1.006-3.413) and high-vancomycin-MIC HA-MRSA (aOR, 2.393; 95% CI, 1.079-5.309), compared with patients with low-vancomycin-MIC CA-MRSA. CONCLUSIONS: The higher risk for treatment failure among patients with traditional hospital-associated MRSA infections, compared with patients with CA-MRSA infections, is independent of the vancomycin MIC, suggesting a potential intrinsic strain-specific virulence effect.
Authors: Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Marianne S Muhlebach; Sonya L Heltshe; Elena B Popowitch; Melissa B Miller; Valeria Thompson; Margaret Kloster; Thomas Ferkol; Wynton C Hoover; Michael S Schechter; Lisa Saiman Journal: Ann Am Thorac Soc Date: 2015-06
Authors: Hannah R Rose; Robert S Holzman; Deena R Altman; Davida S Smyth; Gregory A Wasserman; Jared M Kafer; Michelle Wible; Rodrigo E Mendes; Victor J Torres; Bo Shopsin Journal: J Infect Dis Date: 2014-10-07 Impact factor: 5.226
Authors: Sonya L Heltshe; Lisa Saiman; Elena B Popowitch; Melissa B Miller; Margaret Kloster; Valeria Thompson; Thomas W Ferkol; Wynton C Hoover; Michael S Schechter; Marianne S Muhlebach Journal: J Pediatric Infect Dis Soc Date: 2014-06-09 Impact factor: 3.164
Authors: Warren E Rose; Sanjay K Shukla; Andrew D Berti; Mary S Hayney; Kelsey M Henriquez; Andrea Ranzoni; Matthew A Cooper; Richard A Proctor; Victor Nizet; George Sakoulas Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079